GI Dynamics : Announces EndoBarrier® Therapy Data to be Presented at the 50th Annual Meeting of the European Association for the Study of Diabetes

GI Dynamics Announces EndoBarrier® Therapy Data to be Presented at the 50th Annual Meeting of the European Association for the Study of Diabetes

LEXINGTON, Massachusetts & SYDNEY, Australia - 9 September 2014 - GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that new data on EndoBarrier® Therapy will be presented during five poster presentations at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15-19, 2014, in Vienna, Austria.

The schedule for the EASD presentations is as follows:

Title: Duodenal-Jejunal Bypass Liner Exerts Prompt and Robust Metabolic Changes in Morbidly Obese Patients

Date & Time: Tuesday, September 16 at 2:15 p.m. CEST

Session: PS 080 Gastrointestinal Liners and e-Health Opportunities

Abstract Number: 983

Location: Poster Hall

Presenter: Rodrigo Munoz, M.D., Ph.D., Department of Digestive Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile

Title: Effects of Duodenal-Jejunal Bypass Liner on Plasma Bile Acids in Patients with Severe Obesity

Date & Time: Tuesday, September 16 at 2:15 p.m. CEST

Session: PS 080 Gastrointestinal Liners and e-Health Opportunities

Abstract Number: 982

Location: Poster Hall

Presenter: Andrew Young, M.D., Ph.D., Vice-President, Head of Endocrine Biology, GlaxoSmithKline

Title: The Duodenal-Jejunal Bypass Liner (DJBL) Effect of Regression from Prediabetes

Date & Time: Tuesday, September 16 at 2:15 p.m. CEST

Session: PS 080 Gastrointestinal Liners and e-Health Opportunities

Abstract Number: 984

Location: Poster Hall

Presenter: Veronica Ibarra, M.D., Assistant Professor, Nutrition, Diabetes and Metabolism, Pontificia Universidad Católica de Chile, Santiago, Chile

Title: Acute and Sub-Acute Effects of the EndoBarrier on Glucose Homeostasis and Appetite in Obese Uncontrolled Type 2 Diabetes Mellitus Patients

Date & Time: Tuesday, September 16 at 2:15 p.m. CEST

Session: PS 080 Gastrointestinal Liners and e-Health Opportunities

Abstract Number: 981

Location: Poster Hall

Presenter: Gabriella Lieberman, M.D., Institute of Endocrinology, Sheba Medical Center, Tel Aviv, Israel

Title: Endoscopic, Duodenal-Jejunal Bypass Liner in Obese Patients with or without Type 2 Diabetes Lowers Incidence of Metabolic Syndrome and Improves Cardiovascular Risk

Date & Time: Wednesday, September 17 at 2:15 p.m. CEST

Session: PS 106 Clinical: Hypertension in Diabetes

Abstract Number: 1207

Location: Poster Hall

Presenter: Robert J. Chilton, D.O., F.A.C.C., Professor, Department of Medicine, Division of Cardiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas

About GI Dynamics

GI Dynamics, Inc. (ASX: GID) is the developer of EndoBarrier®, the first endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S. EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. GI Dynamics is conducting a pivotal clinical trial of EndoBarrierin the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com.

Forward-Looking Statements

This presentation contains forward-looking statements based on the current estimates and expectations of future events by the management of GI Dynamics, Inc. as of the date of this presentation and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements. Generally, you can identify forward-looking statements by terms such as "may", "will", "should", "could", "would", "expects", "plans", "anticipates", "believes", "estimates", "projects", "predicts", "potential" and other similar expressions that are intended to identify forward-looking statements, which are generally not historical in nature. All statements that address operating performance, events or developments that GI Dynamics expects or anticipates will occur in the future are forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with estimates of potential revenues; the number and location of commercial centers offering the EndoBarrier®; ability to obtain and maintain regulatory approval for our products; ability to obtain and maintain third-party reimbursement for our products; performance and acceptance of our product, competition; product costs, the timing, costs and outcomes of clinical trials including our pivotal trial; intellectual property risks; risks associated with obtaining funding from third parties; future financial results and other factors including those described in our filings with the U.S. Securities and Exchange Commission and the Australian Securities Exchange.  Given these uncertainties, you should not place undue reliance on these forward-looking statements.  We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.